Copy to clipboard 
Paragon 28 reported 4Q22 orthopedic sales of $51.5 million, +20.4% compared to 4Q21. For the full year, the company generated $181.4 million in orthopedic sales, +23% compared to 2021.
The company launched ten new products in 2022 and expanded its salesforce by 15%. Some of those new products opened up new categories for Paragon 28, like external fixation and soft tissue.
The company expects to commercialize parts of its Smart 28 technology ecosystem starting in late-2023 and 2024. The acquisition of Disior provided a key component to the ecosystem.
“Three-dimensional awareness is critical to realigning and restoring function to the foot,” said Paragon 28 CEO Albert DaCosta. “There’s no better tool than software to help give surgeons the three-dimensional perspective of both diagnosing the deformity as well as predicting how to best correct and realign the feet right for gait and better outcomes. So Disior was one of the most significant pieces for us in our SMART 28 aspirations there.”
Mindful of the uncertain economic environment, Paragon 28 expects 2023 orthopedic sales growth between 18% and 20%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Extremity Joint Replacement | $2.4 | $2.0 | $0.4 | 20.4% |
| Trauma | $44.5 | $37.0 | $7.5 | 20.3% |
| Sports Medicine | $2.0 | $1.6 | $0.4 | 25.2% |
| Orthobiologics | $2.5 | $2.1 | $0.4 | 18% |
| Total | $51.5 | $42.8 | $8.7 | 20.4% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Extremity Joint Replacement | $7.8 | $6.2 | $1.6 | 25% |
| Trauma | $158.8 | $129.1 | $29.6 | 23% |
| Sports Medicine | $6.7 | $5.3 | $1.4 | 26.8% |
| Orthobiologics | $8.2 | $6.8 | $1.3 | 19% |
| Total | $181.4 | $147.5 | $33.9 | 23% |
Orthopedic Sales by Geography
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $45.3 | $38.1 | $7.3 | 19.1% |
| OUS | $6.2 | $4.7 | $1.5 | 31.4% |
| Total | $51.5 | $42.8 | $8.7 | 20.4% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $158.1 | $130.1 | $28.0 | 21.5% |
| OUS | $23.3 | $17.4 | $5.9 | 33.9% |
| Total | $181.4 | $147.5 | $33.9 | 23% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $51.5 | |
| Cost of Sales | $9.5 | 18.5% |
| R & D | $6.6 | 12.7% |
| Selling and Admin | $44.5 | 86.3% |
| Other | $29.7 | 57.7% |
| Net Earnings | ($38.8) | (75.3%) |
Paragon 28 reported 4Q22 orthopedic sales of $51.5 million, +20.4% compared to 4Q21. For the full year, the company generated $181.4 million in orthopedic sales, +23% compared to 2021.
The company launched ten new products in 2022 and expanded its salesforce by 15%. Some of those new products opened up new categories for Paragon 28, like...
Paragon 28 reported 4Q22 orthopedic sales of $51.5 million, +20.4% compared to 4Q21. For the full year, the company generated $181.4 million in orthopedic sales, +23% compared to 2021.
The company launched ten new products in 2022 and expanded its salesforce by 15%. Some of those new products opened up new categories for Paragon 28, like external fixation and soft tissue.
The company expects to commercialize parts of its Smart 28 technology ecosystem starting in late-2023 and 2024. The acquisition of Disior provided a key component to the ecosystem.
“Three-dimensional awareness is critical to realigning and restoring function to the foot,” said Paragon 28 CEO Albert DaCosta. “There’s no better tool than software to help give surgeons the three-dimensional perspective of both diagnosing the deformity as well as predicting how to best correct and realign the feet right for gait and better outcomes. So Disior was one of the most significant pieces for us in our SMART 28 aspirations there.”
Mindful of the uncertain economic environment, Paragon 28 expects 2023 orthopedic sales growth between 18% and 20%.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Extremity Joint Replacement | $2.4 | $2.0 | $0.4 | 20.4% |
| Trauma | $44.5 | $37.0 | $7.5 | 20.3% |
| Sports Medicine | $2.0 | $1.6 | $0.4 | 25.2% |
| Orthobiologics | $2.5 | $2.1 | $0.4 | 18% |
| Total | $51.5 | $42.8 | $8.7 | 20.4% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Extremity Joint Replacement | $7.8 | $6.2 | $1.6 | 25% |
| Trauma | $158.8 | $129.1 | $29.6 | 23% |
| Sports Medicine | $6.7 | $5.3 | $1.4 | 26.8% |
| Orthobiologics | $8.2 | $6.8 | $1.3 | 19% |
| Total | $181.4 | $147.5 | $33.9 | 23% |
Orthopedic Sales by Geography
| 4Q22 | 4Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $45.3 | $38.1 | $7.3 | 19.1% |
| OUS | $6.2 | $4.7 | $1.5 | 31.4% |
| Total | $51.5 | $42.8 | $8.7 | 20.4% |
| FY22 | FY21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $158.1 | $130.1 | $28.0 | 21.5% |
| OUS | $23.3 | $17.4 | $5.9 | 33.9% |
| Total | $181.4 | $147.5 | $33.9 | 23% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $51.5 | |
| Cost of Sales | $9.5 | 18.5% |
| R & D | $6.6 | 12.7% |
| Selling and Admin | $44.5 | 86.3% |
| Other | $29.7 | 57.7% |
| Net Earnings | ($38.8) | (75.3%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
